Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

ABSTRACT:

Background

The increasingly complex programs of contemporary cancer therapy emphasize the need for biological indicators of both therapeutic response and adverse effects. One example is combined-modality treatment aimed at improving long-term outcome in patients with locally advanced rectal cancer, which commonly comes at the price of extended limits of patient tolerance.

Methods

In a prospective study with intensified neoadjuvant treatment of rectal cancer patients, using an antibody array, the profiling of approximately 500 proteins was performed in serial serum samples collected at different stages of the treatment course.

Results

The small number of proteins whose levels significantly changed after induction neoadjuvant chemotherapy (NACT) expanded substantially f

SUBMITTER: Kalanxhi E 

PROVIDER: S-EPMC4962367 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature